Shanghai Junshi Biosciences Coの浮動株式数
Shanghai Junshi Biosciences Coの浮動株式数は何ですか。
Shanghai Junshi Biosciences Co., Ltd.の浮動株式数は563.057M 256.76%です。
浮動株式数の定義は何ですか。
浮動株式数は、ロックインされた株式とは対照的に、公的投資家の手にある企業の株式の一部です。
Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded
The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.
OTCのセクタHealth Careにおける浮動株式数の企業と比べるShanghai Junshi Biosciences Co
Shanghai Junshi Biosciences Coは何をしますか。
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Shanghai Junshi Biosciences Coと類似の浮動株式数
- China Oil Gangranの浮動株式数は561.441M 22.16%です。
- Power of Canadaの浮動株式数は562.284M 90.44%です。
- Power of Canadaの浮動株式数は562.284M 90.44%です。
- Centeneの浮動株式数は562.381M 136.93%です。
- IDBI Bankの浮動株式数は562.685M 5.23%です。
- Shandong International Trust Coの浮動株式数は563.022M 48.34%です。
- Shanghai Junshi Biosciences Coの浮動株式数は563.057M 256.76%です。
- Octopus Renewables Infrastructure Trust PLCの浮動株式数は563.221M 99.70%です。
- Boill Healthcareの浮動株式数は564.168M 41.54%です。
- China Baoli Technologiesの浮動株式数は564.317M 101.09%です。
- Computershareの浮動株式数は564.402M 93.49%です。
- Computershareの浮動株式数は564.445M 93.49%です。
- Newborn Townの浮動株式数は565.052M 51.42%です。